This drug, which inhibits viral replication, could offer a unique adjunctive treatment for glioblastoma, particularly in patients who exhibit high viral loads, test positive for IgM or show evidence of HCMV infection within their tumour tissues. This evidence concerns the gene CD40LG and neoplasm.